Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Gil-Solsona R, Nika MC, Bustamante M, Villanueva CM, Foraster M, Cosin-Tomas M, Alygizakis N, Gomez-Roig MD, Llurba-Olive E, Sunyer J, Thomaidis NS, Dadvand P, Gago-Ferrero P. The potential of sewage sludge to predict and evaluate the human chemical exposome. Environ Sci Technol Lett. 2021 Dec 14;8(12):1077-84. doi: 10.1021/acs.estlett.1c00848